证券之星消息，12月16日，深港通医疗(港币)（983036）指数报收于4264.99点，跌0.54%，成交79.31亿 元，换手率0.81%。当日该指数成份股中，上涨的有17家，福瑞股份以4.6%的涨幅领涨，下跌的有41 家，健康之路以5.81%的跌幅领跌。 深港通医疗(港币)（983036）指数十大成份股详情如下： | 深港通医疗(港币)指数 十大成份股 | | --- | | 证券代码 | 股票简称 | 权重 | 最新价 | 涨跌幅 | 总市值(亿元) | 所属行业 | | --- | --- | --- | --- | --- | --- | --- | | hk02587 | 健康之路 | | 3.97 | -5.81% | 34.85 | 计算机 | | hk02522 | 一脉阳光 | i | 8.23 | -4.93% | 32.59 | 医药生物 | | hk06086 | 方丹健客 | | 2.48 | -4.55% | 33.20 | 医药生物 | | sz301584 | 建发致新 | -- | 31.07 | -3.87% | 130.89 | 医药生物 | | hk02609 | ...

证券代码：301267 证券简称：华厦眼科 公告编号：2025-036 华厦眼科医院集团股份有限公司 2025 年中期分红派息实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指 引第 9 号——回购股份》等相关规定，华厦眼科医院集团股份有限公司（以下简 称"公司"或"本公司"）回购专用账户中的股份不参与本次分红派息。公司 2025 年中期分红派息以当前总股本 840,000,000 股剔除已回购股份 7,527,840 股 后的 832,472,160 股为基数，向全体股东每 10 股派发现金红利人民币 0.90 元（含 税），合计派发现金红利 74,922,494.40 元。 2、本次分红派息实施后计算除权除息价格时，以公司总股本（含回购股份， 即 840,000,000 股）折算后的每 10 股现金红利（含税）=现金分红总额/总股本（含 回购股份）*10=74,922,494.40 元/840,000,000 股*10=0.891934 元（保留六位小数， 最后一位直接截 ...

Core Insights - The "2025 Fifth China Health Industry Development and Rehabilitation Service Conference" was successfully held in Beijing, focusing on integrating resources and exploring development paths in the health industry [1] - The conference featured high-level discussions on cutting-edge topics such as innovative drugs, brain-machine interfaces, AI in healthcare, and the transformation of traditional Chinese medicine [1] - A series of innovative case studies were released, showcasing advancements in various categories including ESG, innovative drugs, biotechnology, and AI healthcare [1] Company Summaries - **Shanghai Raist**: Demonstrates leadership in the blood products industry with a systematic approach to ESG, including waste reduction and energy management, and has received AA and BBB ratings from Wind and MSCI respectively [3] - **Yuyue Medical**: Focuses on high-quality medical products and services, with a commitment to social responsibility and green production practices [4] - **Darentang**: Implements a sustainable development system that integrates governance, management, and operations, aligning with national climate goals [5] - **Kelaiying**: Integrates sustainability into its strategy, enhancing ESG management and promoting green transformation in the pharmaceutical industry [6] - **Jiuzhoutong**: A technology-driven pharmaceutical service provider that emphasizes green practices and social responsibility, with significant donations for disaster relief [7] - **Lianbang Pharmaceutical**: A leading comprehensive pharmaceutical company that emphasizes green development and social responsibility, with a strong focus on product accessibility [8] - **Tongchen Beijian**: Implements a comprehensive green management strategy, achieving significant carbon reductions and engaging in extensive public welfare initiatives [9] - **Betaini**: Integrates ESG principles into its long-term strategy, achieving high ratings and engaging in biodiversity and community support initiatives [10] - **Huaxia Eye Hospital**: Actively practices sustainable development and social responsibility, contributing to rural healthcare and social equity [11] - **Boteng Co.**: Establishes a robust ESG framework, focusing on green chemistry and social responsibility, with a commitment to employee development [12] - **Shuoshi Biotechnology**: Engages in green production and public health initiatives, enhancing accessibility to healthcare through innovative technologies [13] - **Qilu Pharmaceutical**: Aims to meet public health needs with a strong focus on quality and international standards, achieving significant sales and export figures [14] - **Qing Song Health Group**: Develops a comprehensive digital health ecosystem using AI and big data, enhancing accessibility and promoting proactive health management [15]

Core Insights - The conference held by Huaxia Eye Hospital Group focused on strategic planning and academic discussions to enhance eye health in China, aligning with the "14th Five-Year Plan" [4][14] - The event gathered numerous experts and leaders in the field, emphasizing the importance of collaboration and innovation in advancing the eye care industry [1][2] Group 1: Strategic Planning and Development - The conference aimed to clarify the development trajectory of the eye care sector and explore new paths for growth in alignment with the "14th Five-Year Plan" [4][6] - Huaxia Eye Hospital's "1236" development plan is being implemented, marking a significant year for strategic initiatives and academic advancements [6][13] - The establishment of the ophthalmology department at Xiamen University Medical School and partnerships with other institutions are part of the strategic expansion efforts [13][10] Group 2: Technological Innovation and Digital Transformation - Huaxia Eye Hospital is embracing digital transformation by integrating advanced technologies such as AI and big data into its healthcare services, enhancing patient experience [24][23] - The hospital has implemented various innovative practices, including an AI screening system for diabetic retinopathy and a remote consultation network with nearly 100 hospitals [24][23] - The focus on "Artificial Intelligence+" aims to improve clinical services and operational efficiency, addressing diverse patient needs [24][23] Group 3: Research and Academic Collaboration - The establishment of multiple research platforms, including national and provincial key laboratories, supports the hospital's commitment to scientific innovation and collaboration [31][34] - The conference featured discussions on the integration of research and clinical practice, highlighting the importance of a comprehensive innovation system [31][34] - Experts shared insights on the future of ophthalmology and the role of research in driving advancements in the field [17][19] Group 4: Future Vision and Commitment - Huaxia Eye Hospital aims to continue its trajectory of growth and innovation, focusing on patient-centered services and sustainable development [48][46] - The hospital's leadership emphasizes the importance of strategic direction and expert collaboration in navigating the evolving healthcare landscape [44][46] - The commitment to enhancing eye health services aligns with national health strategies and the goal of establishing a world-class eye care institution [48][46]

证券日报网讯12月4日，华厦眼科（301267）在互动平台回答投资者提问时表示，公司长期专注于眼科 医疗服务，已经建立了全国连锁运营的诊疗服务体系。公司正按照发展战略规划，通过自建及并购方 式，稳步推进全国医疗服务网络布局。 ...

Group 1 - The Shenzhen Stock Exchange announced a periodic adjustment of sample stocks for various indices, including the Shenzhen Component Index and the ChiNext Index, effective December 15, 2025 [1] - Huaxia Eye Hospital (301267) is one of the stocks being removed from the ChiNext Index sample list [1] Group 2 - Huaxia Eye Hospital was listed on the ChiNext on November 7, 2022, with an initial offering price of 50.88 RMB per share and is currently in a state of decline [2] - The total funds raised from the initial public offering amounted to 305.28 million RMB, with a net amount of 276.85 million RMB after deducting issuance costs [2] - The company originally planned to raise 77.85 million RMB for various projects, including hospital construction and operational upgrades, but ultimately raised 198.99 million RMB more than planned [2] Group 3 - In the 2022 annual shareholders' meeting held on May 15, 2023, the company approved a profit distribution plan, distributing a cash dividend of 2.8 RMB per 10 shares, totaling 15.68 million RMB [3] - The company also approved a capital reserve increase, converting 5 shares for every 10 shares held, increasing the total share capital from 56 million shares to 84 million shares [3] - Huaxia Eye Hospital Group was established in 2004 in Xiamen, Fujian Province, with a registered capital of 84 million RMB [3]

自"十四五"规划明确提出实施城市更新行动以来，关于城市更新的政策、法规、模式层出叠见。智通财 经旗下智库澎湃研究所以《城市更新·简报》这一形式搭建城市更新信息平台，聚焦城市更新试点及示 范城市，关注政府、市场与社会多元主体动态，精选各级政府及媒体一月（2025年11月1日-2025年11月 30日）重要政策及行动，呈现城市更新最新理念、策略及成效，推动城市可持续发展。 头条： 全国城市更新工作推进会在安徽芜湖召开 11月21日，住房城乡建设部在安徽省芜湖市召开全国城市更新工作推进会，研究部署高质量开展城市更 新，推动建设创新、宜居、美丽、韧性、文明、智慧的现代化人民城市。 会议指出，要认真贯彻落实《中共中央办公厅国务院办公厅关于持续推进城市更新行动的意见》，因地 制宜、探索创新，着力在规划、资金、运营、治理4个方面下功夫。下功夫编制好城市更新专项规划， 建立城市体检与城市更新一体化推进机制，建立完善"专项规划—片区策划—项目实施方案"规划实施体 系，做好规划衔接；下功夫建立可持续的城市建设运营投融资体系，统筹用好各类资金，发挥政府资金 撬动作用，鼓励金融机构开发金融产品，提供长周期、低利率的信贷支持；下功夫建 ...

Investment Rating - The report does not explicitly state an investment rating for the ophthalmology industry Core Insights - The ophthalmology medical service market in China is experiencing stable growth, with the market size projected to reach CNY 2,521.5 billion by 2025, reflecting a compound annual growth rate (CAGR) of 16.0% from 2020 to 2025 [7][10] - The revenue structure of companies in the industry is diversifying, with a notable increase in the proportion of refractive and optical services, while the basic medical sector faces pressure from policy changes and demand structure [3][50] - The overall growth rate of ophthalmology hospitals is slowing, with private hospitals expected to increase to 3,044 by 2028, while public hospitals will only expand to 83 [10][11] Company Summaries - Aier Eye Hospital continues to lead the industry with a revenue of CNY 174.84 billion, showing a 7.3% year-on-year growth, demonstrating strong risk resistance [25][29] - Huaxia Eye Hospital reported a revenue of CNY 32.7 billion, with a slight increase of 2.8% year-on-year, while its net profit rose by 3% to CNY 4.3 billion [25][26] - Puri Eye Hospital achieved a revenue of CNY 22.01 billion, with a 3.0% increase, but its net profit saw a significant drop of 66.1% due to new hospital losses and high expenses [25][30] - He Eye Hospital's revenue decreased by 1.1% to CNY 8.6 billion, but its net profit surged by 232.2% to CNY 0.54 billion, benefiting from regional business optimization [25][30] - Xima Medical reported a revenue of CNY 8.6 billion in 2025H1, a 61.29% increase year-on-year, achieving breakeven in mainland China operations [41][41] Market Dynamics - The proportion of refractive income is increasing across companies, with Puri Eye Hospital leading at 49.34%, followed by Aier Eye Hospital at 40.13% [50][47] - The cataract income share is declining, particularly for Huaxia Eye Hospital, which dropped from 22.70% to 20.15% due to the impact of centralized procurement policies [50][51] - The report highlights a trend of increasing high-end surgical procedures, which is driving up average transaction prices in the industry [58]

Core Viewpoint - The report highlights the significant growth in the number of myopia patients in China, indicating a rising demand for ophthalmic medical services and a robust market potential for eye care due to increasing health awareness and an aging population [1] Industry Summary - The number of myopia patients in China increased from 540 million in 2016 to 660 million in 2020, with the national myopia prevalence rising from 39.2% to 47.1% [1] - The demand for refractive surgery is expected to grow continuously as awareness of vision health increases and the number of myopia patients rises [1] - The aging population and enhanced health consciousness among the elderly are projected to expand the demand for cataract and other eye disease treatments, indicating a vast market potential for ophthalmic medical services [1] Company Summary - Huaxia Eye Hospital is recognized as a leading private ophthalmic medical enterprise in China, with strong academic capabilities and a clear expansion model [1] - The company is expected to maintain steady growth in performance, driven by the anticipated recovery in consumer healthcare, continuous upgrades in refractive surgical techniques, and increased demand for medical services due to aging trends [1] - Projected net profits for Huaxia Eye Hospital are estimated to reach 482 million, 552 million, and 629 million yuan for the years 2025, 2026, and 2027, respectively [1]

Core Insights - On November 24, brokerages set target prices for listed companies, with notable increases for Fangsheng Pharmaceutical, Juhua Co., and Meihua Biological, showing target price increases of 46.38%, 38.81%, and 32.68% respectively, all belonging to the traditional Chinese medicine and chemical products industries [1][2]. Group 1: Target Price Increases - Fangsheng Pharmaceutical received a target price of 16.60 yuan, reflecting a target price increase of 46.38% [2]. - Juhua Co. was assigned a target price of 46.00 yuan, indicating a target price increase of 38.81% [2]. - Meihua Biological's target price was set at 13.44 yuan, with a target price increase of 32.68% [2]. - Other companies with significant target price increases include Toukeng Life (28.14% increase) and Yiling Pharmaceutical (18.30% increase) [2]. Group 2: Brokerage Recommendations - On November 24, a total of 23 listed companies received brokerage recommendations, with companies like Keshun Co., Jinhong Group, and Meihua Biological receiving one recommendation each [2]. - Fangsheng Pharmaceutical was covered for the first time by Guotai Junan Securities with an "Increase" rating [3]. - Other companies receiving first-time coverage include Linuo Pharmaceutical (Increase rating), Yinglian Co. (Increase rating), Huaxia Eye Hospital (Recommendation rating), and Yike Medical (Outperform rating) [3].